DHGWA
VRTX icon

Dixon Hughes Goodman Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$2K Hold
9
– – ﹤0.01% 744
2021
Q4 		$2K Buy
+9
New +$1.75K ﹤0.01% 702

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's VRTX Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2022 at 9 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #744.

Dixon Hughes Goodman Wealth Advisors first reported a position in VRTX in Q4 2021 and has held it in 2 quarters since. 1,071 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

  • Dixon Hughes Goodman Wealth Advisors held 9 shares of Vertex Pharmaceuticals worth $2K as of Q1 2022.
  • Dixon Hughes Goodman Wealth Advisors left its Vertex Pharmaceuticals share count unchanged in Q1 2022.
  • Vertex Pharmaceuticals made up ﹤0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #744 holding.
  • Dixon Hughes Goodman Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • 1,071 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.